News | June 04, 2007

Heart Patch Helps Damaged Cardiac Tissue Heal

June 5, 2007 — A patch designed to help damaged cardiac tissue recover from a heart attack has been successful in early animal testing and is moving toward potential human use, researchers report.

"It is a biodegradable, porous polyurethane scaffold that is placed atop the infarcted [damaged] region of the heart," explained study author William R. Wagner, a professor of surgery and bioengineering at the University of Pittsburgh. "It changes the environment during the remodeling process, and degrades over several months. The impact of it is to have a thicker heart wall."

His group reports on the patch in the June 12 issue of the Journal of the American College of Cardiology.

In a trial with rats that had induced heart attacks, the patch was implanted directly on the damaged part of the heart wall. The wall was thicker, "with abundant smooth muscle bundles," and healthier, mature heart cells, the researchers reported.

The patch is not designed to help produce new, contracting cells in the damaged part of the heart, Wagner stressed. Researchers at other institutions are working toward that goal, he said, "but our patch is more like a biodegradable girdle that changes the way the heart feels through a mechanical effect."

One advantage of the approach is that it could lead to quicker use of the technology in humans, Wagner said.

"It doesn't contain any cells that require attention from a regulatory perspective," he said. "We can suture it onto the heart, which allows a minimally invasive approach."

When and if the technology is used in humans, the patch will be implanted about two weeks after a heart attack, Wagner said. "That's when the heart becomes more symptomatic," he added.

A next step toward human use has started in a trial with pigs, a larger animal whose responses are more similar to those of people, Wagner said.

"We hope to complete the pig study this year," he said. "If then we are looking at positive results in this larger animal, it would mean we could do a clinical trial."

"We haven't paired up with a company yet," but such a commercial partnership would be necessary to bring the technology to market, Wagner said.

"From a theoretical perspective, it is reasonable to believe that it will work," he said. "It would alter the healing response so that the heart wall would not thin out and would have mechanical properties that preserve its function."

For more information visit:

Related Content

Sponsored Content | Videos | Cardiovascular Ultrasound| July 19, 2017
This video educational session, provided in partnership with the American Society of Echocardiography (ASE), is title
Pre-PCI Impella 2.5 Insertion Improves Survival in Left Main Coronary Artery Heart Attacks
News | Ventricular Assist Devices (VAD)| June 30, 2017
Abiomed Inc. announced the recent publication of a peer-reviewed retrospective study on hemodynamic support with the...
Italian Boy Becomes Youngest Patient Bridged to Transplant With SynCardia Total Artificial Heart

Andrei, 12, is the world’s youngest patient to be bridged to transplant with the SynCardia Total Artificial Heart. He is pictured after his heart transplant with his surgeon, Antonio Amodeo, M.D., at Bambino Gesù Children’s Hospital in Rome, Italy. Photo courtesy of Business Wire.

News | Congenital Heart| June 22, 2017
A 12-year-old boy at Bambino Gesù Children’s Hospital in Rome, Italy, has become the world’s youngest patient to be...
Abiomed Impella CP pVAD, third-generation CP
Technology | Hemodynamic Support Devices| June 12, 2017
June 12, 2017 — Abiomed Inc.
tandemLife Tandemheart priming tray cleared by FDA
Technology | Hemodynamic Support Devices| June 12, 2017
June 12, 2017 — TandemLife began its commercial launch of the TandemLife Priming Tray, a new product designed to simp
Sponsored Content | Videos | Cardiovascular Ultrasound| May 26, 2017
This video, provided in partnership with the American Society of Echocardiography (ASE), is titled "Intraoperative Tr
Impella CP study to investigate door to left ventricular unloading time
News | May 09, 2017
May 9, 2017 — The first patient has been enrolled in the U.S.
Heartware HVAD recall for its ventricular assist device from Medtronic
Feature | Ventricular Assist Devices (VAD)| May 05, 2017
May 5, 2017 — Medtronic Mechanical Circulatory Support is expanding its recall of its HeartWare Ventricular Assist De
the Impella pVAD improves survival, mortality in AMI heart attack with cardiogenic shock

Early use of the Impella percutaneous ventricular assist device prior to angioplasty may significantly improve survival for patients in cardiogenic shock.

Feature | Hemodynamic Support Devices| April 28, 2017 | Dave Fornell
Recent clinical study data presented at the American College of Cardiology (ACC) 2017 meeting show new treatment prot
Sponsored Content | Videos | Ventricular Assist Devices (VAD)| April 14, 2017
A discussion with William O'Neill, M.D., FACC, FSCAI, medical director of the Center for Structural Heart Disease at
Overlay Init